All In Biotech

Drug Trial Radar · NCT06525597

Study of Stapokibart Injection in Patients With Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Stapokibart Injection in Patients With Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 30, 2024

Primary completion

Oct 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

  • Stapokibart InjectionBiological

    IL-4Rα monoclonal antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 4 weeks of treatment.Time frame: Up to week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, CMU

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.